PROVIDER PROFILE · NPI 1043506728
Qiyuan DaiMD
MEDICARE UTILIZATION · PART B · 2024
No data available for this provider in 2024.
PRESCRIBING · PART D · 2024
Total Rx claims
4,124
Beneficiaries
—
Total drug cost
$100K
Distinct drugs
77
Brand share
13.9%
Top prescribed drugs
Atorvastatin Calcium479 claims
Amlodipine Besylate236 claims
Rosuvastatin Calcium235 claims
Lisinopril215 claims
Losartan Potassium191 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2025
No data available for this provider in 2025.
REFERRAL NETWORK
Where Qiyuan Dai's patients come from & go
Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 1 inbound referrers · 5 outbound destinations.
Receives referrals from
Inbound — who sends patients here
| Physician | Patients | Visits |
|---|---|---|
| Unilab Corporation Clinical Laboratory · West Hills, CA | 45 | 110 |
Refers patients to
Outbound — where patients go next
| Physician | Patients | Visits |
|---|---|---|
| ANTELOPE VALLEY COMMUNITY CLINIC | 123 | 494 |
| Unilab Corporation Clinical Laboratory · West Hills, CA | 52 | 141 |
| Latara Enterprise Inc. Clinical Laboratory · Pomona, CA | 34 | 106 |
| LANCASTER HOSPITAL CORPORATION | 18 | 63 |
| Advanced Endoscopy And Pain Center Llc Ambulatory Surgical Center · Lancaster, CA | 13 | 16 |
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
CROSS-REFERENCE